Enhanced Functionality of Anti-GPC3 CAR-T Cells Against Hepatocellular Carcinoma Through Locoregional Administration.

ABSTRACT:

Background & aims

The prognosis for patients with hepatocellular carcinoma (HCC) remains suboptimal, despite the rapid advancement of anti-cancer immunotherapy. Chimeric antigen receptor (CAR) T cell therapy targeting glypican-3 (GPC3) has been developed for HCC; however, clinical trials have demonstrated heterogeneous responses among patients and limited CAR-T cell infiltration. Locoregional administration has emerged as a promising strategy for CAR-T therapy against solid tumours, yet its potential for HCC treatment has not been thoroughly explored.

Methods

In this study, we constructed anti-GPC3 CAR-T cells and examined their therapeutic efficacy through locoregional and systemic administration using multiple HCC xenograft mouse models.

Results

Comparison of CAR-T

SUBMITTER: Wang J 

PROVIDER: S-EPMC12635792 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature